UBIVE hosts a research team and the National Reference Center (NRC) for Viral Hemorrhagic Fevers (VHF). Research focuses on VHF, in particular Lassa fever caused by Lassa virus, but also Ebola virus. We try to understand the molecular mechanisms involved in the pathogenesis of Lassa fever using animal and primary cell culture models. We study in particular the role of the immune response in the control of infections. We have access to several pathogenic and nonpathogenic arenaviruses thus allowing BSL-4 and BSL-2 studies. We also develop prophylactic and therapeutic approaches against Lassa fever and other arenaviruses. The NRC for VHF links fundamental research and clinical and/or field investigations. Through this activity, new viral strains and biological samples are collected. The NRC also performs applied research and surveillance and expertise activities, like the development of new tools or the study of viral diversity in the wild fauna. Notably, the NRC for FHV has been highly involved in France and on the field in Western Africa during the 2014 Ebola outbreak.
The institut Carnot Pasteur MS
Carnot, label of excellence Founded in 2006, the Carnot Label, granted by the French government, was designed to develop partnership-based research, meaning research conducted by public laboratories in partnership with socio-economic players, primarily industry […]
LabEx IBEID – Integrative Biology of Emerging Infectious Diseases
Presentation The aim of the Integrative Biology of Emerging Infectious Diseases (IBEID) project, coordinated by Professors Philippe Sansonetti and Pascale Cossart, is to develop a structure to anticipate and tackle emerging infectious diseases (EIDs). […]
2021A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains., Sci Transl Med 2021 Jun; 13(597): .
2021Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques., Commun Biol 2021 Jan; 4(1): 27.
2020Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus., Emerg Microbes Infect 2020 Dec; 9(1): 1761-1770.
2020Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials., CPT Pharmacometrics Syst Pharmacol 2020 May; 9(5): 258-271.
2020Rational design of universal immunotherapy for TfR1-tropic arenaviruses., Nat Commun 2020 01; 11(1): 67.
2019A 40-Month Follow-Up of Ebola Virus Disease Survivors in Guinea (PostEbogui) Reveals Long-Term Detection of Ebola Viral Ribonucleic Acid in Semen and Breast Milk., 2019 Dec; 6(12): ofz482.
2019Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot., Sci Transl Med 2019 10; 11(512): .
2019Fatal Case of Lassa Fever, Bangolo District, Côte d’Ivoire, 2015, Emerging Infect. Dis. 2019 Sep;25(9):1753-1756.
2019Autophagy Promotes Infectious Particle Production of Mopeia and Lassa Viruses, Viruses 2019 03;11(3).
2019Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus, Viruses 2019 03;11(3).
+View full list of publications
Phone: + 33 4 37 28 24 40 Email: firstname.lastname@example.org Address 21 avenue Tony Garnier, 69007 LYON France